ORG 25935
Alternative Names: Glycine uptake inhibitor; ORG25935; SCH 900435Latest Information Update: 05 Nov 2023
At a glance
- Originator Organon
- Developer Merck & Co; Organon
- Class Tetrahydronaphthalenes
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Panic disorder; Schizophrenia
Most Recent Events
- 03 Mar 2010 Discontinued - Phase-II for Panic disorder in USA (PO)
- 24 Feb 2010 Schering-Plough completes enrolment in a phase II trial for panic disorders in USA
- 15 Jan 2008 Pharmacodynamics data from a preclinical study in rats and monkeys presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)